Primary erythromelalgia: a review

Orphanet Journal of Rare Diseases

Hong Jiang¹  Beisha Tang¹  Zhao Chen²  Zhaoli Tang² 

[1] State Key Lab of Medical Genetics, Central South University, 110 Xiangya road, Changsha, Hunan, China;Department of Neurology, Xiangya Hospital, Central South University, 87 Xiangya road, Changsha, Hunan, China

关键词: Therapy;    Hyper-excitability;    Electrophysiology;    Genetics;    Pain;    Voltage-gated sodium channel;    Primary erythromelalgia;   

Others  :  1228433
DOI  :  10.1186/s13023-015-0347-1

 received in 2015-07-10, accepted in 2015-09-24,  发布年份 2015

【 摘 要 】

Primary erythromelalgia (PE ORPHA90026) is a rare autosomal dominant neuropathy characterized by the combination of recurrent burning pain, warmth and redness of the extremities. The incidence rate of PE ranges from 0.36 to 1.1 per 100,000 persons. Gender ratio differs according to different studies and no evidence showed a gender preference. Clinical onset of PE is often in the first decade of life. Burning pain is the most predominant symptom and is usually caused and precipitated by warmth and physical activities. Reported cases of PE contain both inherited and sporadic forms. Genetic etiology of PE is mutations on SCN9A, the encoding gene of a voltage-gated sodium channel subtype Nav1.7. Diagnosis of PE is made upon clinical manifestations and screening for mutations on SCN9A. Exclusion of several other treatable diseases/secondary erythromelalgia is also necessary because of the lack of biomarkers specifically for PE. Differential diagnoses can include Fabry disease, cellulites, Raynaud phenomenon, vasculitis and so on. Diagnostic methods often involve complete blood count, imaging studies and thermograph. Treatment for PE is unsatisfactory and highly individualized. Frequently used pain relieving drugs involve sodium channel blockers such as lidocaine, carbamazepine and mexiletine. Novel drugs such as PF-05089771 and TV-45070 could be promising in ameliorating pain symptoms due to their Nav1.7 selectivity. Patients’ symptoms often worsen over time and many patients develop ulcerations and gangrenes caused by excessive exposure to low temperature in order to relieve pain. This review mainly focuses on PE and the causative gene SCN9A -- its mutations and their effects on Nav1.7 channels’ electrophysiological properties. We propose a genotype-channelopathy-phenotype correlation network underlying PE etiology which could provide guidance for future therapeutics.

【 授权许可】

   
2015 Tang et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Ji RR, Xu ZZ, Gao YJ. Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov. 2014; 13:533-48.
• [2]Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain. 2010; 11:1230-9.
• [3]Drenth JP, van Genderen PJ, Michiels JJ. Thrombocythemic erythromelalgia, primary erythermalgia, and secondary erythermalgia: three distinct clinicopathologic entities. Angiology. 1994; 45:451-3.
• [4]Michiels JJ, Drenth JP, Van Genderen PJ. Classification and diagnosis of erythromelalgia and erythermalgia. Int J Dermatol. 1995; 34:97-100.
• [5]Davis MD, O'Fallon WM, Rogers RS, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol. 2000; 136:330-6.
• [6]Mork C, Kvernebo K. Erythromelalgia--a mysterious condition? Arch Dermatol. 2000; 136:406-9.
• [7]Mork C, Kalgaard OM, Myrvang B, Kvernebo K. Erythromelalgia in a patient with AIDS. J Eur Acad Dermatol Venereol. 2000; 14:498-500.
• [8]van Genderen PJ, Michiels JJ. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost. 1997; 23:357-63.
• [9]Briere JB. Essential thrombocythemia. Orphanet J Rare Dis. 2007; 2:3.
• [10]Kalgaard OM, Seem E, Kvernebo K. Erythromelalgia: a clinical study of 87 cases. J Intern Med. 1997; 242:191-7.
• [11]Alhadad A, Wollmer P, Svensson A, Eriksson KF. Erythromelalgia: Incidence and clinical experience in a single centre in Sweden. Vasa. 2012; 41:43-8.
• [12]Reed KB, Davis MD. Incidence of erythromelalgia: a population-based study in Olmsted County, Minnesota. J Eur Acad Dermatol Venereol. 2009; 23:13-5.
• [13]Stadler T, O'Reilly AO, Lampert A. Erythromelalgia mutation Q875E Stabilizes the activated state of sodium channel Nav1.7. J Biol Chem. 2015; 290:6316-25.
• [14]Meijer IA, Vanasse M, Nizard S, Robitaille Y, Rossignol E. An atypical case of SCN9A mutation presenting with global motor delay and a severe pain disorder. Muscle Nerve. 2014; 49:134-8.
• [15]Eberhardt M, Nakajima J, Klinger AB, Neacsu C, Huhne K, O'Reilly AO et al.. Inherited pain: sodium channel Nav1.7 A1632T mutation causes erythromelalgia due to a shift of fast inactivation. J Biol Chem. 2014; 289:1971-80.
• [16]Yang Y, Estacion M, Dib-Hajj SD, Waxman SG. Molecular architecture of a sodium channel S6 helix: radial tuning of the voltage-gated sodium channel 1.7 activation gate. J Biol Chem. 2013; 288:13741-7.
• [17]Klein CJ, Wu Y, Kilfoyle DH, Sandroni P, Davis MD, Gavrilova RH et al.. Infrequent SCN9A mutations in congenital insensitivity to pain and erythromelalgia. J Neurol Neurosurg Psychiatry. 2013; 84:386-91.
• [18]Estacion M, Yang Y, Dib-Hajj SD, Tyrrell L, Lin Z, Yang Y et al.. A new Nav1.7 mutation in an erythromelalgia patient. Biochem Biophys Res Commun. 2013; 432:99-104.
• [19]Cregg R, Laguda B, Werdehausen R, Cox JJ, Linley JE, Ramirez JD et al.. Novel mutations mapping to the fourth sodium channel domain of Nav1.7 result in variable clinical manifestations of primary erythromelalgia. Neuromolecular Med. 2013; 15:265-78.
• [20]Estacion M, Han C, Choi JS, Hoeijmakers JG, Lauria G, Drenth JP et al.. Intra- and interfamily phenotypic diversity in pain syndromes associated with a gain-of-function variant of NaV1.7. Mol Pain. 2011; 7:92.
• [21]Cheng X, Dib-Hajj SD, Tyrrell L, Te Morsche RH, Drenth JP, Waxman SG. Deletion mutation of sodium channel Na(V)1.7 in inherited erythromelalgia: enhanced slow inactivation modulates dorsal root ganglion neuron hyperexcitability. Brain. 2011; 134:1972-86.
• [22]Estacion M, Choi JS, Eastman EM, Lin Z, Li Y, Tyrrell L et al.. Can robots patch-clamp as well as humans? Characterization of a novel sodium channel mutation. J Physiol. 2010; 588:1915-27.
• [23]Cheng X, Dib-Hajj SD, Tyrrell L, Wright DA, Fischer TZ, Waxman SG. Mutations at opposite ends of the DIII/S4-S5 linker of sodium channel Na V 1.7 produce distinct pain disorders. Mol Pain. 2010; 6:24.
• [24]Lampert A, Dib-Hajj SD, Eastman EM, Tyrrell L, Lin Z, Yang Y et al.. Erythromelalgia mutation L823R shifts activation and inactivation of threshold sodium channel Nav1.7 to hyperpolarized potentials. Biochem Biophys Res Commun. 2009; 390:319-24.
• [25]Han C, Dib-Hajj SD, Lin Z, Li Y, Eastman EM, Tyrrell L et al.. Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation. Brain. 2009; 132:1711-22.
• [26]Estacion M, Dib-Hajj SD, Benke PJ, Te Morsche RH, Eastman EM, Macala LJ et al.. NaV1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci. 2008; 28:11079-88.
• [27]Cheng X, Dib-Hajj SD, Tyrrell L, Waxman SG. Mutation I136V alters electrophysiological properties of the Na(v)1.7 channel in a family with onset of erythromelalgia in the second decade. Mol Pain. 2008; 4:1.
• [28]Sheets PL, Jackson JO, Waxman SG, Dib-Hajj SD, Cummins TR. A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity. J Physiol. 2007; 581:1019-31.
• [29]Lee MJ, Yu HS, Hsieh ST, Stephenson DA, Lu CJ, Yang CC. Characterization of a familial case with primary erythromelalgia from Taiwan. J Neurol. 2007; 254:210-4.
• [30]Lampert A, Dib-Hajj SD, Tyrrell L, Waxman SG. Size matters: Erythromelalgia mutation S241T in Nav1.7 alters channel gating. J Biol Chem. 2006; 281:36029-35.
• [31]Harty TP, Dib-Hajj SD, Tyrrell L, Blackman R, Hisama FM, Rose JB et al.. Na(V)1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons. J Neurosci. 2006; 26:12566-75.
• [32]Han C, Rush AM, Dib-Hajj SD, Li S, Xu Z, Wang Y et al.. Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7. Ann Neurol. 2006; 59:553-8.
• [33]Choi JS, Dib-Hajj SD, Waxman SG. Inherited erythermalgia: limb pain from an S4 charge-neutral Na channelopathy. Neurology. 2006; 67:1563-7.
• [34]Michiels JJ, te Morsche RH, Jansen JB, Drenth JP. Autosomal dominant erythermalgia associated with a novel mutation in the voltage-gated sodium channel α subunit Nav1. 7. Archives Neurology. 2005; 62:1587-90.
• [35]Dib-Hajj SD, Rush AM, Cummins TR, Hisama FM, Novella S, Tyrrell L et al.. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain. 2005; 128:1847-54.
• [36]Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L et al.. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004; 41:171-4.
• [37]Friberg D, Chen T, Tarr G, van Rij A. Erythromelalgia? A clinical study of people who experience red, hot, painful feet in the community. Int J Vasc Med. 2013; 2013:864961.
• [38]Segerdahl AR, Xie J, Paterson K, Ramirez JD, Tracey I, Bennett DL. Imaging the neural correlates of neuropathic pain and pleasurable relief associated with inherited erythromelalgia in a single subject with quantitative arterial spin labelling. Pain. 2012; 153:1122-7.
• [39]Nurowska-Wrzosek B, Tolodziecka L, Gaciong Z. Erythromelalgia: two case reports and literature review. Pol Arch Med Wewn. 2007; 117:322-6.
• [40]Skeik N, Rooke TW, Davis MD, Davis DM, Kalsi H, Kurth I et al.. Severe case and literature review of primary erythromelalgia: novel SCN9A gene mutation. Vasc Med. 2012; 17:44-9.
• [41]Messeguer F, Agusti-Mejias A, Vilata Corell JJ, Requena C. Auricular erythromelalgia: report of a rare case. Dermatol Online J. 2013; 19:16.
• [42]Bennett DL, Woods CG. Painful and painless channelopathies. Lancet Neurol. 2014; 13:587-99.
• [43]Takahashi K, Saitoh M, Hoshino H, Mimaki M, Yokoyama Y, Takamizawa M et al.. A case of primary erythermalgia, wintry hypothermia and encephalopathy. Neuropediatrics. 2007; 38:157-9.
• [44]Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain. 2004; 108:237-47.
• [45]Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. From genes to pain: Na v 1.7 and human pain disorders. Trends Neurosci. 2007; 30:555-63.
• [46]Dib-Hajj SD, Estacion M, Jarecki BW, Tyrrell L, Fischer TZ, Lawden M et al.. Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable. Mol Pain. 2008; 4:37.
• [47]Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K et al.. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006; 444:894-8.
• [48]Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. Sodium channels in normal and pathological pain. Annu Rev Neurosci. 2010; 33:325-47.
• [49]Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev. 2005; 57:397-409.
• [50]Isom LL, Catterall WA. Na + channel subunits and Ig domains. Nature. 1996; 383:307-8.
• [51]Amir R, Argoff CE, Bennett GJ, Cummins TR, Durieux ME, Gerner P et al.. The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain. 2006; 7:S1-29.
• [52]Yu FH, Catterall WA. Overview of the voltage-gated sodium channel family. Genome Biol. 2003;4.
• [53]Bezanilla F. The voltage sensor in voltage-dependent ion channels. Physiol Rev. 2000; 80:555-92.
• [54]Hille B. The permeability of the sodium channel to metal cations in myelinated nerve. J Gen Physiol. 1972; 59:637-58.
• [55]Patton DE, West JW, Catterall WA, Goldin AL. Amino acid residues required for fast Na(+)-channel inactivation: charge neutralizations and deletions in the III-IV linker. Proc Natl Acad Sci U S A. 1992; 89:10905-9.
• [56]Liu M, Wood JN. The roles of sodium channels in nociception: implications for mechanisms of neuropathic pain. Pain Med. 2011; 12 Suppl 3:S93-9.
• [57]Waxman SG, Dib-Hajj S. Erythermalgia: molecular basis for an inherited pain syndrome. Trends Mol Med. 2005; 11:555-62.
• [58]Sangameswaran L, Fish LM, Koch BD, Rabert DK, Delgado SG, Ilnicka M et al.. A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root ganglia. J Biol Chem. 1997; 272:14805-9.
• [59]Nassar MA, Stirling LC, Forlani G, Baker MD, Matthews EA, Dickenson AH et al.. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci U S A. 2004; 101:12706-11.
• [60]Klugbauer N, Lacinova L, Flockerzi V, Hofmann F. Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J. 1995; 14:1084-90.
• [61]Cummins TR, Howe JR, Waxman SG. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J Neurosci. 1998; 18:9607-19.
• [62]Herzog RI, Cummins TR, Ghassemi F, Dib-Hajj SD, Waxman SG. Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J Physiol. 2003; 551:741-50.
• [63]Blair NT, Bean BP. Roles of tetrodotoxin (TTX)-sensitive Na + current, TTX-resistant Na + current, and Ca2+ current in the action potentials of nociceptive sensory neurons. J Neurosci. 2002; 22:10277-90.
• [64]Renganathan M, Cummins TR, Waxman SG. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J Neurophysiol. 2001; 86:629-40.
• [65]Drenth JP, Finley WH, Breedveld GJ, Testers L, Michiels JJ, Guillet G et al.. The primary erythermalgia-susceptibility gene is located on chromosome 2q31-32. Am J Hum Genet. 2001; 68:1277-82.
• [66]Zhang LL, Lin ZM, Ma ZH, Xu Z, Yang YL, Yang Y. Mutation hotspots of SCN9A in primary erythermalgia. Br J Dermatol. 2007; 156:767-9.
• [67]Wu MT, Huang PY, Yen CT, Chen CC, Lee MJ. A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers. PLoS One. 2013; 8: Article ID e55212
• [68]Rush AM, Dib-Hajj SD, Liu S, Cummins TR, Black JA, Waxman SG. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc Natl Acad Sci U S A. 2006; 103:8245-50.
• [69]Cummins TR, Zhou J, Sigworth FJ, Ukomadu C, Stephan M, Ptacek LJ et al.. Functional consequences of a Na + channel mutation causing hyperkalemic periodic paralysis. Neuron. 1993; 10:667-78.
• [70]Lehmann-Horn F, Kuther G, Ricker K, Grafe P, Ballanyi K, Rudel R. Adynamia episodica hereditaria with myotonia: a non-inactivating sodium current and the effect of extracellular pH. Muscle Nerve. 1987; 10:363-74.
• [71]Sangameswaran L, Delgado SG, Fish LM, Koch BD, Jakeman LB, Stewart GR et al.. Structure and function of a novel voltage-gated, tetrodotoxin-resistant sodium channel specific to sensory neurons. J Biol Chem. 1996; 271:5953-6.
• [72]Vandenberg CA, Bezanilla F. A sodium channel gating model based on single channel, macroscopic ionic, and gating currents in the squid giant axon. Biophys J. 1991; 60:1511-33.
• [73]Attwell D, Cohen I, Eisner D, Ohba M, Ojeda C. The steady state TTX-sensitive ("window") sodium current in cardiac Purkinje fibres. Pflugers Arch. 1979; 379:137-42.
• [74]Caffrey JM, Eng DL, Black JA, Waxman SG, Kocsis JD. Three types of sodium channels in adult rat dorsal root ganglion neurons. Brain Res. 1992; 592:283-97.
• [75]Harper AA, Lawson SN. Electrical properties of rat dorsal root ganglion neurones with different peripheral nerve conduction velocities. J Physiol. 1985; 359:47-63.
• [76]Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci. 2004; 24:8232-6.
• [77]Djouhri L, Newton R, Levinson SR, Berry CM, Carruthers B, Lawson SN. Sensory and electrophysiological properties of guinea-pig sensory neurones expressing Nav1.7 (PN1) Na + channel α subunit protein. J Physiol. 2003; 546:565-76.
• [78]Waxman SG. Sodium channels, the electrogenisome and the electrogenistat: lessons and questions from the clinic. J Physiol. 2012; 590:2601-12.
• [79]Toledo-Aral JJ, Moss BL, He ZJ, Koszowski AG, Whisenand T, Levinson SR et al.. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc Natl Acad Sci U S A. 1997; 94:1527-32.
• [80]Raymond CK, Castle J, Garrett-Engele P, Armour CD, Kan Z, Tsinoremas N et al.. Expression of alternatively spliced sodium channel alpha-subunit genes. Unique splicing patterns are observed in dorsal root ganglia. J Biol Chem. 2004; 279:46234-41.
• [81]Choi JS, Cheng X, Foster E, Leffler A, Tyrrell L, Te Morsche RH et al.. Alternative splicing may contribute to time-dependent manifestation of inherited erythromelalgia. Brain. 2010; 133:1823-35.
• [82]Swensen AM, Bean BP. Robustness of burst firing in dissociated purkinje neurons with acute or long-term reductions in sodium conductance. J Neurosci. 2005; 25:3509-20.
• [83]Kalgaard OM, Clausen OP, Mellbye OJ, Hovig T, Kvernebo K. Nonspecific capillary proliferation and vasculopathy indicate skin hypoxia in erythromelalgia. Arch Dermatol. 2011; 147:309-14.
• [84]Davis MD, Weenig RH, Genebriera J, Wendelschafer-Crabb G, Kennedy WR, Sandroni P. Histopathologic findings in primary erythromelalgia are nonspecific: special studies show a decrease in small nerve fiber density. J Am Acad Dermatol. 2006; 55:519-22.
• [85]Zheng ZM, Zhang JH, Hu JM, Liu SF, Zhu WP. Poxviruses isolated from epidemic erythromelalgia in China. Lancet. 1988; 1:296.
• [86]Clarke JT. Narrative review: Fabry disease. Ann Intern Med. 2007; 146:425-33.
• [87]Davis MD, Sandroni P. Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. Arch Dermatol. 2005; 141:1320-1.
• [88]Iqbal J, Bhat MI, Charoo BA, Syed WA, Sheikh MA, Bhat IN. Experience with oral mexiletine in primary erythromelalgia in children. Ann Saudi Med. 2009; 29:316-8.
• [89]Choi JS, Zhang L, Dib-Hajj SD, Han C, Tyrrell L, Lin Z et al.. Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off. Exp Neurol. 2009; 216:383-9.
• [90]Sheets PL, Heers C, Stoehr T, Cummins TR. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J Pharmacol Exp Ther. 2008; 326:89-99.
• [91]Rush AM, Elliott JR. Phenytoin and carbamazepine: differential inhibition of sodium currents in small cells from adult rat dorsal root ganglia. Neurosci Lett. 1997; 226:95-8.
• [92]Song JH, Nagata K, Huang CS, Yeh JZ, Narahashi T. Differential block of two types of sodium channels by anticonvulsants. Neuroreport. 1996; 7:3031-6.
• [93]Natkunarajah J, Atherton D, Elmslie F, Mansour S, Mortimer P. Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel. Clin Exp Dermatol. 2009; 34:e640-2.
• [94]Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M et al.. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet. 2007; 71:311-9.
• [95]Salat K, Kowalczyk P, Gryzlo B, Jakubowska A, Kulig K. New investigational drugs for the treatment of neuropathic pain. Expert Opin Investig Drugs. 2014; 23:1093-104.
• [96]Goldberg YP, Price N, Namdari R, Cohen CJ, Lamers MH, Winters C et al.. Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012; 153:80-5.
• [97]Pharma X. http://www.xenon-pharma.com/product-candidates/pain/pain-teva/ Accessed 17 Sep 2015.
• [98]Priest BT, Blumenthal KM, Smith JJ, Warren VA, Smith MM. ProTx-I and ProTx-II: gating modifiers of voltage-gated sodium channels. Toxicon. 2007; 49:194-201.
• [99]Schmalhofer WA, Calhoun J, Burrows R, Bailey T, Kohler MG, Weinglass AB et al.. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol Pharmacol. 2008; 74:1476-84.
• [100]Yeomans DC, Levinson SR, Peters MC, Koszowski AG, Tzabazis AZ, Gilly WF et al.. Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Nav1.7 sodium channels in primary afferents. Hum Gene Ther. 2005; 16:271-7.
• [101]Nakajima Y, Koizumi K, Hirata T, Hirai K, Sakamoto A, Shimizu K. Successful thoracoscopic sympathectomy for primary erythromelalgia in the upper extremities. Jpn J Thorac Cardiovasc Surg. 2004; 52:524-6.
• [102]Kim MK, Yuk JW, Kim HS, Park KJ, Kim DS. Autonomic dysfunction in SCN9A-associated primary erythromelalgia. Clin Auton Res. 2013; 23:105-7.
• [103]Ahn HS, Dib-Hajj SD, Cox JJ, Tyrrell L, Elmslie FV, Clarke AA et al.. A new Nav1.7 sodium channel mutation I234T in a child with severe pain. Eur J Pain. 2010; 14:944-50.
• [104]Yang Y, Dib-Hajj SD, Zhang J, Zhang Y, Tyrrell L, Estacion M et al.. Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a Na(V)1.7 mutant channel. Nat Commun. 2012; 3:118.
• [105]Fischer TZ, Gilmore ES, Estacion M, Eastman E, Taylor S, Melanson M et al.. A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. Ann Neurol. 2009; 65:733-41.
• [106]Vasylyev DV, Han C, Zhao P, Dib-Hajj S, Waxman SG. Dynamic-clamp analysis of wild-type human Nav1.7 and erythromelalgia mutant channel L858H. J Neurophysiol. 2014; 111:1429-43.